EGA
UTHR icon

Eagle Global Advisors’s United Therapeutics UTHR Stock Holding History

Eagle Global Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276K Buy
510
+10
+2% +$5.63K 0.01% 249
2026
Q1 		$296K Hold
500
– – 0.01% 241
2025
Q4 		$244K Hold
500
– – 0.01% 259
2025
Q3 		$210K Buy
+500
New +$168K 0.01% 268
2017
Q3 		– Sell
-1,589
Closed -$206K – 360
2017
Q2 		$206K Buy
+1,589
New +$198K 0.01% 377

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Eagle Global Advisors's UTHR Position: Q2 2026 in Review

Eagle Global Advisors increased its United Therapeutics (UTHR) stake by 2% in Q2 2026, buying an estimated $5.63K and bringing the position to 510 shares worth $276K. The position accounts for 0.01% of the portfolio, ranked #249.

Eagle Global Advisors first reported a position in UTHR in Q2 2017 and has held it in 5 quarters since. The position peaked at $296K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Eagle Global Advisors held 510 shares of United Therapeutics worth $276K as of Q2 2026.
  • Eagle Global Advisors bought 10 United Therapeutics shares in Q2 2026, an estimated $5.63K.
  • United Therapeutics made up 0.01% of Eagle Global Advisors's portfolio in Q2 2026, its #249 holding.
  • Eagle Global Advisors first reported a position in United Therapeutics in Q2 2017 and has held it in 5 quarters since.
  • Eagle Global Advisors's United Therapeutics position peaked at $296K in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Eagle Global Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.